Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia
- 1 July 1989
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 24 (S1) , S16-S19
- https://doi.org/10.1007/bf00253232
Abstract
Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P<0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.Keywords
This publication has 0 references indexed in Scilit: